Price
No data yet.
Social Signal Score
Revenue
$1.42MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wing Fung Siu
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 87
- Beta
- -0.04
- Country
- TH
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.70
Financials
Revenue
$1.42M-6.2%Net Income
$-7.67MEBITDA
$-7.27MFree Cash Flow
—EPS (diluted)
$-117.36Shares Outstanding (diluted)
65.4K+124.4%Operating Expenses
$5.50MCash & Debt
$758.6KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.73M | $9.88M | $151.20 |
| 2024 | $5.43M | $-525.0K | $-200.76 |
| 2023 | $5.14M | $130.2K | $111.92 |
| 2022 | $5.94M | $458.7K | $562.64 |
| 2021 | $4.12M | $-533.00 | $-0.04 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $222.10
- Implied price
- $3,998
- Return from $0.13
- 691.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1,988 — today's price is already 100.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 562.0% | 592.2% | 617.9% | 640.4% | 660.4% |
| 3.0% | 595.7% | 627.5% | 654.5% | 678.1% | 699.2% |
| 8.0% | 629.5% | 662.8% | 691.1% | 715.9% | 738.0% |
| 13.0% | 663.3% | 698.1% | 727.8% | 753.7% | 776.8% |
| 18.0% | 697.0% | 733.4% | 764.4% | 791.4% | 815.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5d ago·Neutral
NewGen Announces Closing of $1.25 Million Public Offering BANGKOK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross procee…
View source ↗ - Newsglobenewswire.com·7d ago·Positive
NewGen Announces Pricing of $1.25 Million Public Offering BANGKOK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expe…
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
NewGenIVF Completes Exchange of Convertible Notes with Institutional Investor BANGKOK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today announced that it has completed an exchange agreement with a certain institutional investor (“Investor”) pursuant to which existing convertible notes held by the Investor were exchanged for a new senior convertible note on amended terms. The exchange close…
View source ↗
Earnings
Wed, Mar 3(in 5 months)
Consensus estimate $24.48 per share
Typical surprise -49.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Sep 2$18.18 vs $18.18beat
- Wed, Apr 1$4.59 vs $417.15miss
Estimates and results for NIVF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NIVF officers and directors.
- Bought
- $4.4m
- Sold
- $119k
8 trades
2 trades
- Cheung Kong Yiubought
- Cheung Kong Yiubought
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Cheung Kong Yiubought
- Hrt Financial Lpbought
- Cheung Kong Yiubought
- Hrt Financial Lpsold
22 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NIVF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.